Author

Kerry B. Contini (US)

Browsing

On May 12, 2025, the White House issued a wide-reaching Executive Order (“EO“) titled “Delivering Most Favored Nation Prescription Drug Pricing to American Patients” for the stated purpose of ensuring that American patients will have access to the most-favored-nation (“MFN“) price for prescription drugs and biologics.1  This EO came out about one month after the release of EO No. 14273 titled “Lowering Drug Prices by Once Again Putting Americans First” (April 15, 2025) which outlined…

Please join Baker McKenzie and ACC Minnesota at Hewing Hotel on Wednesday, May 1st to hear from the international speakers, bringing perspective from the US, EMEA, Asia and LATAM. Focusing on the evolving global geopolitical landscape, they will discuss the legal and compliance considerations that play an increasingly central role in mitigating against geopolitical risks and informing critical business decisions. Click here for additional information about this program for in-house counsel and to register

Baker McKenzie’s Global Compliance News Blog published “Global: 2022: International Trade Developments in a Challenging New World,” which can be viewed here.